Compare FSTR & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSTR | SGMT |
|---|---|---|
| Founded | 1902 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.6M | 238.7M |
| IPO Year | N/A | 2023 |
| Metric | FSTR | SGMT |
|---|---|---|
| Price | $28.67 | $6.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.71 |
| AVG Volume (30 Days) | 30.4K | ★ 626.9K |
| Earning Date | 11-03-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $507,819,000.00 | N/A |
| Revenue This Year | $3.42 | N/A |
| Revenue Next Year | $3.88 | N/A |
| P/E Ratio | $63.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.16 | $1.73 |
| 52 Week High | $29.42 | $11.41 |
| Indicator | FSTR | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 53.84 | 39.48 |
| Support Level | $28.00 | $5.80 |
| Resistance Level | $29.30 | $6.33 |
| Average True Range (ATR) | 0.96 | 0.41 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 51.89 | 25.32 |
L.B. Foster Co is a U.S-based firm engaged in the manufacturing, fabrication, and distribution of products and services, especially for the rail, construction, energy, and utility industries. The company operates its business through two segments: Rail Technologies and Services and Infrastructure Solutions. Its principal business activity involves providing new and used rail, trackwork, and accessories, producing concrete railroad ties, insulated rail joints, power rail, track fasteners, cover boards, and sales of sells and rents steel sheet piling, H-bearing pile, and other piling products for foundation and earth retention requirements. It generates the majority of its revenues from the Rail Technologies and Services segment.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.